Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 418.10
Bid: 416.20
Ask: 416.40
Change: -1.50 (-0.36%)
Spread: 0.20 (0.048%)
Open: 421.30
High: 422.20
Low: 415.50
Prev. Close: 419.60
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

21 Oct 2021 07:00

RNS Number : 7297P
Rentokil Initial PLC
21 October 2021
 

  

 

21 October 2021

RENTOKIL INITIAL PLC (RTO) - THIRD QUARTER TRADING UPDATE

Strong momentum across our core businesses in Q3, continued good execution of M&A

 

 

(£m)

Q3 2021

Growth

AER

AER

CER

Ongoing Revenue1

761.3

0.9%

4.8%

Revenue

761.9

0.5%

4.4%

Excluding Disinfection

Ongoing Revenue1

750.2

10.2%

14.5%

Revenue

750.8

9.7%

14.0%

 

Overview of Q3 performance (at CER)

Q3 saw continued strong momentum in our core businesses with Group Ongoing Revenue, excluding disinfection services, growing by 14.5%, of which 6.7% was Organic2 and 7.8% was from acquisitions.

Pest Control delivered an excellent performance overall during the period. Despite our Australian, New Zealand, Malaysian and Indonesian operations being materially impacted by lockdowns in Q3, the category grew Ongoing Revenues by 18.3%, of which 7.5% was Organic. Ongoing Revenue in our Growth and Emerging markets grew by 18.7% and 15.6% respectively. In our North America business, a higher number of colleagues either off work with COVID-19 or self-isolating contributed to some labour shortages in the quarter. Despite this, our Pest Control business in North America continued to demonstrate very strong momentum, growing revenues by 24.6%, 10.1% Organic.

Our Core Hygiene business, excluding disinfection, delivered a 6.4% increase in Ongoing Revenue (4.7% Organic), reflecting good performances in the UK, Europe and Latin America but held back, as with Pest Control, by significant challenges associated with lockdowns and movement restrictions in Australia, New Zealand, Indonesia and Malaysia.

Sales from disinfection services have tapered in line with our expectations at £11.4m (Q1: £75.7m, Q2: £22.6m), a decline of £62.1m on this time last year. We are maintaining our guidance for disinfection revenues in H2 to be within the range of £10m to £20m.

Ongoing Revenue in our Protect & Enhance category grew by 6.2% (5.5% Organic), reflecting further recovery in our France Workwear, Ambius, UK Property Care and Dental Hygiene services businesses.

New category structure - Hygiene & Wellbeing

At our Capital Markets Day on 28 September, we announced that in response to the increasing importance of hygiene and wellbeing services, we are expanding our Hygiene category with effect from 1 January 2022. The enlarged category, called Hygiene & Wellbeing, will comprise our current Hygiene operations together with our Ambius, Dental Hygiene and Cleanroom services operations, previously part of our Protect & Enhance category. Adopting the new category structure in Q3 would give organic growth in Hygiene & Wellbeing of 6.6%.

M&A

​We completed nine acquisitions in Q3: seven in Pest Control; one in Hygiene; and the previously announced transaction with Boecker, which completed on 3 August and which offers both Pest Control and Hygiene services. As a result, we have acquired businesses with operations in Australia, Chile, Colombia, Guadeloupe, Lebanon, Saudi Arabia, United Arab Emirates and the US, as well as interests in affiliated businesses in Kuwait, Qatar and Nigeria. Together, these have combined annualised revenues in the year prior to acquisition of c.£48m. Q2's excellent momentum has been maintained in Q3 and also into Q4, and our anticipated full year expenditure on M&A remains in the region of at least £450m to £500m, as previously guided.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have delivered a strong performance from our core businesses in the quarter and are confident of sustaining this momentum for the remainder of the year. Assuming no further significant deterioration in trading conditions arising from the pandemic, our performance in Q3 - combined with further progress in our value-creating M&A programme - means we remain on track to deliver a full year performance in line with the guidance given at our interim results in July."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2020 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPGUAUUPGGQU
Date   Source Headline
1st May 20157:00 amRNS1st Quarter Results
22nd Apr 20154:01 pmRNSHolding(s) in Company
10th Apr 201510:03 amRNSAnnual Financial Report
8th Apr 20154:34 pmRNSHolding(s) in Company
1st Apr 20154:59 pmRNSDirector/PDMR Shareholding
27th Mar 20154:00 pmRNSHolding(s) in Company
19th Mar 20157:00 amRNSAcquisitions and completion of bond issue
11th Mar 20154:34 pmRNSHolding(s) in Company
10th Mar 20153:54 pmRNSChange to Director's details
5th Mar 201510:21 amRNSHolding(s) in Company
27th Feb 20157:00 amRNSPreliminary Results 31.12.14
23rd Jan 20153:56 pmRNSHolding(s) in Company
8th Jan 20157:00 amRNSRentokil Initial acquisitions
6th Jan 20154:43 pmRNSDirectorate Change
3rd Dec 201412:25 pmRNSChange to PDMR details
26th Nov 20145:50 pmRNSHolding(s) in Company
24th Nov 20144:03 pmRNSHolding(s) in Company
7th Nov 20147:00 amRNSQ3 Interim Management Statement
24th Oct 201410:33 amRNSHolding(s) in Company
15th Oct 20141:33 pmRNSHolding(s) in Company
13th Oct 201411:33 amRNSHolding(s) in Company
11th Sep 20141:23 pmRNSHolding(s) in Company
1st Aug 20147:00 amRNSHalf Yearly Report
30th Jul 20147:00 amRNSCompany Secretary Change
25th Jul 20142:14 pmRNSHolding(s) in Company
22nd Jul 20147:00 amRNSDirectorate Change
3rd Jul 20145:00 pmRNSHolding(s) in Company
18th Jun 201410:18 amRNSHolding(s) in Company
6th Jun 20144:45 pmRNSHolding(s) in Company
3rd Jun 201410:17 amRNSTotal Voting Rights
23rd May 20145:03 pmRNSDirector/PDMR Shareholding
21st May 20147:00 amRNSDirector/PDMR Shareholding
15th May 201412:12 pmRNSAGM Statement
2nd May 20147:00 amRNS1st Quarter Results
22nd Apr 20149:51 amRNSHolding(s) in Company
11th Apr 201411:41 amRNSPublication of 2013 Annual Report & Board Changes
3rd Apr 20144:52 pmRNSHolding(s) in Company
1st Apr 20145:13 pmRNSDirector/PDMR Shareholding
18th Mar 20144:28 pmRNSHolding(s) in Company
18th Mar 20142:12 pmRNSHolding(s) in Company
18th Mar 20147:00 amRNSCompletion of sale of Initial Facilities
14th Mar 201410:56 amRNSHolding(s) in Company
13th Mar 20145:16 pmRNSHolding(s) in Company
11th Mar 20143:59 pmRNSHolding(s) in Company
10th Mar 201412:22 pmRNSHolding(s) in Company
10th Mar 201410:57 amRNSHolding(s) in Company
5th Mar 20147:00 amRNSAcquisition
3rd Mar 20143:02 pmRNSHolding(s) in Company
28th Feb 20147:02 amRNSSale of Initial Facilities
28th Feb 20147:02 amRNSPreliminary Results 31.12.13 and disposal

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.